KR102114490B1 - 지주막하 출혈 및 허혈에 대한 치료법 - Google Patents

지주막하 출혈 및 허혈에 대한 치료법 Download PDF

Info

Publication number
KR102114490B1
KR102114490B1 KR1020147019192A KR20147019192A KR102114490B1 KR 102114490 B1 KR102114490 B1 KR 102114490B1 KR 1020147019192 A KR1020147019192 A KR 1020147019192A KR 20147019192 A KR20147019192 A KR 20147019192A KR 102114490 B1 KR102114490 B1 KR 102114490B1
Authority
KR
South Korea
Prior art keywords
delete delete
peptide
pharmaceutical composition
subjects
tat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147019192A
Other languages
English (en)
Korean (ko)
Other versions
KR20140108266A (ko
Inventor
마이클 티미안스키
Original Assignee
노노 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2762338A external-priority patent/CA2762338C/en
Application filed by 노노 인코포레이티드 filed Critical 노노 인코포레이티드
Publication of KR20140108266A publication Critical patent/KR20140108266A/ko
Application granted granted Critical
Publication of KR102114490B1 publication Critical patent/KR102114490B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147019192A 2011-12-13 2012-12-13 지주막하 출혈 및 허혈에 대한 치료법 Expired - Fee Related KR102114490B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161570264P 2011-12-13 2011-12-13
US61/570,264 2011-12-13
CA2762338A CA2762338C (en) 2011-12-13 2011-12-15 Therapy for subarachnoid hemorrhage and ischemia
CA2,762,338 2011-12-15
US201261617001P 2012-03-28 2012-03-28
US61/617,001 2012-03-28
PCT/IB2012/057259 WO2013088382A1 (en) 2011-12-13 2012-12-13 Therapy for subarachnoid hemorrhage and ischemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207014227A Division KR20200057802A (ko) 2011-12-13 2012-12-13 지주막하 출혈 및 허혈에 대한 치료법

Publications (2)

Publication Number Publication Date
KR20140108266A KR20140108266A (ko) 2014-09-05
KR102114490B1 true KR102114490B1 (ko) 2020-05-25

Family

ID=51228598

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147019192A Expired - Fee Related KR102114490B1 (ko) 2011-12-13 2012-12-13 지주막하 출혈 및 허혈에 대한 치료법
KR1020207014227A Ceased KR20200057802A (ko) 2011-12-13 2012-12-13 지주막하 출혈 및 허혈에 대한 치료법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207014227A Ceased KR20200057802A (ko) 2011-12-13 2012-12-13 지주막하 출혈 및 허혈에 대한 치료법

Country Status (12)

Country Link
EP (1) EP2800575B1 (enExample)
JP (3) JP6279483B2 (enExample)
KR (2) KR102114490B1 (enExample)
CN (1) CN104053448B (enExample)
AU (1) AU2012354072B2 (enExample)
DK (1) DK2800575T3 (enExample)
ES (1) ES2731266T3 (enExample)
IL (1) IL233103B (enExample)
MX (1) MX364562B (enExample)
SG (2) SG10201604676WA (enExample)
WO (1) WO2013088382A1 (enExample)
ZA (1) ZA201404636B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2440230B1 (en) 2009-06-10 2020-11-11 NoNO Inc. Treatment regimes for treatment of neurological disease
PT2723363T (pt) 2011-06-24 2018-11-08 Nono Inc Terapia de combinação para isquemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6633523B2 (ja) * 2013-12-01 2020-01-22 ユニバーシティ オブ コペンハーゲン Ｐｓｄ−９５の二量体阻害剤脂肪酸誘導体
SMT202000307T1 (it) 2014-05-28 2020-07-08 Nono Inc Sale cloruro di tat-nr2b9c
WO2017185250A1 (zh) * 2016-04-27 2017-11-02 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN107312071B (zh) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 兴奋性神经毒性相关损伤的治疗方法
CN109985047B (zh) * 2017-12-29 2021-07-27 广州市赛普特医药科技股份有限公司 5α-雄甾-3β,5,6β-三醇在制备治疗出血性脑卒中药物中的应用
CN109009111A (zh) * 2018-07-16 2018-12-18 重庆大学 低场核磁共振脑出血动态监护仪控制系统
CN113284126B (zh) * 2021-06-10 2022-06-24 安徽省立医院(中国科学技术大学附属第一医院) 人工神经网络图像分析预测脑积水分流手术疗效的方法
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050059597A1 (en) 1999-06-02 2005-03-17 Michael Tymianski Method of reducing injury to mammalian cells
WO2010144721A2 (en) 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brain Research Reviews. Vol. 44, pp. 49-63 (2004)

Also Published As

Publication number Publication date
JP2020128419A (ja) 2020-08-27
KR20140108266A (ko) 2014-09-05
ZA201404636B (en) 2015-10-28
EP2800575B1 (en) 2019-05-22
KR20200057802A (ko) 2020-05-26
SG11201403239UA (en) 2014-09-26
JP2018052962A (ja) 2018-04-05
ES2731266T3 (es) 2019-11-14
AU2012354072A1 (en) 2014-07-03
DK2800575T3 (da) 2019-07-01
JP6279483B2 (ja) 2018-02-14
JP6741642B2 (ja) 2020-08-19
EP2800575A1 (en) 2014-11-12
MX2014007031A (es) 2015-02-20
AU2012354072B2 (en) 2017-04-27
MX364562B (es) 2019-04-30
EP2800575A4 (en) 2015-09-23
CN104053448B (zh) 2017-04-05
IL233103A0 (en) 2014-07-31
WO2013088382A1 (en) 2013-06-20
CN104053448A (zh) 2014-09-17
IL233103B (en) 2021-03-25
JP2015501834A (ja) 2015-01-19
SG10201604676WA (en) 2016-07-28

Similar Documents

Publication Publication Date Title
US11878044B2 (en) Combination therapy for ischemia
US11338015B2 (en) Therapy for subarachnoid hemorrhage and ischemia
EP2800575B1 (en) Therapy for subarachnoid hemorrhage and ischemia
CA2762338C (en) Therapy for subarachnoid hemorrhage and ischemia
HK40003366A (en) Combination therapy for ischemia
HK40003366B (en) Combination therapy for ischemia

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240519

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240519